Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Günter Niegisch MD

Günter Niegisch MD

Professor GU oncology, Department of Urology, University Hospital and Medical Faculty of the Heinrich-Heine-University; Centre for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Düsseldorf, Düsseldorf, Germany

Günter Niegisch is a professor for GU oncology working at the Düsseldorf University Hospital in Germany. Following a training as urologist, he is now focussing on medical treatment of uro-oncological diseases both in general care as well as within the context of clinical trials. Further, he has a focus on translational research in advanced bladder cancer.

Disclosures

Talks, Symposia: Roche Pharma, MEDAC, Pfizer, BMS, AstraZeneca, Merck, Janssen-Cilag, Astellas

Advisory Boards: Roche Pharma, Sanofi, BMS, Merck Serono, Pfizer, MEDAC, Ipsen, Janssen

Travel costs, congress registrations: Roche Pharma, Pfizer, Merck, Janssen

Publications: Pfizer, BMS, Merck

 

Recent Contributions to PracticeUpdate:

  1. Enfortumab Vedotin and Pembrolizumab for Untreated Advanced Urothelial Cancer

Most Read This Week

Recently Updated